Study participant dropout compromises clinical trials by reducing statistical power and potentially biasing findings. We use data from a trial of treatments to delay the progression of mild cognitive impairment to Alzheimer disease (AD) [NEJM 2005;352 (23):79 to 88] to determine predictors of study participant dropout and inform the design and implementation of future trials. Time to study discontinuation was modeled by proportional hazards regression with censoring at incident dementia or trial completion. Of 769 participants, 230 (30%) discontinued prematurely. Risk of dropout was higher among nonwhites [hazard ratio (HR) 2.1, P = 0.0007], participants with less than college education (HR = 1.6, P = 0.02), participants with a Hamilton Depression score of 6 or more (HR = 1.3, P = 0.04), unmarried males (HR = 2.1 relative to married males, P = 0.003) and participants recruited by commercial clinical sites (HR = 2.2 relative to participants recruited by NIA-funded AD research centers, P<0.0001). A trial using commercial sites with the discontinuation rates and incident dementia event rates experienced in this trial would require 80% more participants than a comparably powered trial using NIA-funded AD research center sites. Targeted retention efforts and utilization of academic sites could substantively improve the statistical power and validity of future clinical trials of cognitively impaired elderly.
M issing data are a major concern for all clinical trials.
Prevention trials with long-term follow-up are especially vulnerable to missing data owing to study participant attrition. On the basis of the experience of cohort studies that find that cognitive impairment is a risk factor for study participant attrition, 1,2 loss of participants to follow-up may be especially problematic for secondary prevention trials in dementia. As recently reviewed, 3 this in fact has been the case for most secondary prevention trials conducted to date. Moreover, the literature on causes and risk factors for loss to follow-up within the context of clinical trials is limited. [4] [5] [6] [7] [8] To address these concerns, we investigated predictors of study participant attrition in the Alzheimer Disease Cooperative Study (ADCS) trial of donepezil and vitamin E to delay conversion from amnestic MCI to AD (the ADCS MCI trial 9 ). Knowledge of the factors that influence participant attrition may suggest recruitment and retention strategies to improve the validity and statistical power of future trials.
METHODS
Data from the ADCS MCI trial 9 were used to examine predictors of loss to follow-up owing to death, adverse events, or voluntary participant withdrawal. The trial is described in detail in the report of primary study results (Petersen, et al 9 ) . In brief, this 3-year trial recruited 769 participants from 69 clinical sites in the US and Canada. Inclusion criteria were amnestic MCI of a degenerative nature (insidious onset and gradual progression), impaired memory, a Logical Memory delayed-recall score 10 1.5 standard deviations below educated-adjusted norms, a Clinical Dementia Rating 11 scale score of 0.5, a score of 24 to 30 on the Mini-mental state examination (MMSE 12 ), an age of 55 to 90 years, a Modified Hachinski score 13 of less than or equal to 4, and lack of clinically important depression as indicated by a Hamilton Rating Scale for Depression (HAM-D) 14 score of less than or equal to 12. Sites were also instructed to only recruit participants whose general health and physical condition would not preclude them from completing a 3-year trial. The recruitment period spanned March 1999 to January 2004. Randomization to one of placebo, 2000-IU vitamin E, or 10 mg donepezil was balanced on MMSE score, age, and APOE e4 status. The study was conducted according to Good Clinical Practice guidelines, the Declaration of Helsinki, and the US Code of Federal Regulations Title 21 Part 50 (Protection of Human Subjects) and Title 21 Part 56 (Institutional Review Boards). Written informed consent was obtained from all participants and study partners. Full cognitive exams for incident dementia were conducted on site at 6-month intervals for up to 36 months. Incident dementia was diagnosed by site clinicians, with validation by a secondary review committee. 9 Two-hundred twelve of 214 incident dementia cases met National Institute of Neurological and Communicative Diseases and Stroke and the Alzheimer Disease and Related Disorders Association criteria 15 for possible or probable AD.
Participants who missed scheduled follow-up visits were contacted by site investigators and if they choose to discontinue participation in the study were asked to return for 1 final cognitive exam. Clinical personnel obtained additional information at the final visit or through the telephone if the participant refused to return. The additional information included predefined questions regarding the reasons for study discontinuation. The predefined reasons queried were concern over placebo condition, length of protocol, travel requirements, frequency of assessments, potential adverse effects of medication, concern about medication effectiveness, alternative treatment chosen by participant, alternative treatment chosen by caregiver, or caregiver unwilling to continue.
The analysis plan for this investigation consisted of univariate assessments of possible predictors of study discontinuation followed by a model-building exercise to derive a single multivariate predictive model. The outcome variable was time to discontinuation of the closed-label portion of the trial, defined as the time from baseline to the earliest of the date of progression to dementia or the date of last completed cognitive diagnostic assessment. Participants who did not complete the closed-label portion of the trial were considered events, participants who converted to dementia were censored at the date of dementia diagnosis, and participants who completed the trial without converting to dementia were censored at the date of their month 36 assessment.
Univariate assessments included unweighted log-rank tests of overall association of the covariate with time to study discontinuation, descriptive summaries of the proportion discontinuing by level of the covariate, and Cox proportional hazards model estimates of the relative risk of discontinuation by level of the covariate. Variables significantly related to study discontinuation in univariate log-rank tests at the P<0.1 level were selected for inclusion in the final model; variables related at the P = 0.10 to 0.15 level were subsequently tested for inclusion in the final model and selected for inclusion if likelihood ratio tests to add the term were significant at the P<0.05 level or if there was evidence of confounding by the variable. A covariate was considered to have a mediating or confounding effect if its inclusion in the model altered the model coefficients for other covariate terms by greater than 15% (Hosmer et al 16 ). Interactions with treatment arm were assessed for all variables in the final model and tested with likelihood ratio tests with a Bonferonni adjusted P-value for an overall significance level of 0.05. Interactions significant at the P<0.05 level were included in the final model. The proportional hazards assumption was checked for all term in the final model by Schoenfeld residuals tests using the log transform of time. 17 To investigate the extent to which observed associations were driven by deaths and other serious adverse events, we did 2 sensitivity analyses, first refitting the final model with censoring on death, and again refitting the final model with censoring on both death and discontinuation owing to other serious adverse events. The distribution of continuous variables was compared using the Wilcoxon signed rank test and the frequency of categorical variables was compared using the Fisher exact test, as indicated. All analyses were conducted using the R statistical programming language, 18 with log-rank tests and Cox modeling done using the R library ''survival.''
Covariates considered included the screening measurements of Logical Memory, MMSE, modified Hachinski scale, and HAM-D, and measurements of activities of daily living using the ADCS Mild Cognitive Impairment Activities of Daily Living Scale, 19 BMI (weight in kilograms divided by the square of height in meters), the Clinical Dementia Rating scale sum of boxes (CDR sum of boxes 20 ), and the Global Deterioration Scale. 21 Informant questionnaires and interviews were used to obtain study participant age, race/ethnicity, primary language, education, marital status, the Beck Informant Depression Scale, 22 duration of cognitive impairment prior to enrollment, living arrangement, and information on the informant relation to the study participant and hours per week informant spends with participant. Treatment arm was categorized per the ADCS MCI trial as placebo, vitamin E, or donepezil. Type of recruitment site was categorized as National Institute of Aging program project AD research centers (ADC sites), non-ADC, university-affiliated research centers (universityaffiliated sites), or commercial sites not affiliated with a university (commercial sites).
RESULTS
Of the 769 participants randomized into the trial, 214 incident dementias were observed, 325 participants completed the 36-month trial without converting to dementia, and 230 (30%) did not complete the closed-label phase of the trial. Of the 230 noncompleters, 17 participants died, 47 were discontinued by site clinicians owing to adverse events, 105 withdrew consent during the trial, 55 discontinued the treatment and ultimately withdrew consent during the trial, and 6 moved or otherwise refused further contact. Study discontinuation occurred within the first 6 months for 117 participants and within the first year for 172 participants. Over four-fifths of those lost (193, 83.9%) dropped by 18th month, with 9.6%, 5.7%, and 0.9% dropping in each of the remaining 6-month intervals. Overall, the mean length in study was 23.2 months [standard deviation (SD) 13.4], with participants who discontinued completing an average of 9.5 months (SD 8.9) of follow-up, compared with 18.4 months (SD 9.1) for incident dementia cases and 36.0 (SD 0.4) for those who completed the closed-label portion of the trial without converting to dementia.
Baseline characteristics by discontinuation status are presented in Table 1 . Participants who dropped were different from those who continued in the study on several demographic measures. In univariate analyses, risk of study discontinuation was higher among females (HR = 1.36, P = 0.020), among nonwhite participants compared with white, non-Hispanic participants (HR = 2.12, P<0.001), and among those with less than high school education (HR = 1.51, P = 0.047). Rates of study discontinuation were highest at commercial sites (43.8%), and lowest at ADCs (23.0%, P<0.001). University-affiliated sites had slightly higher rates of study discontinuation compared with ADCs (28.5%, P = 0.150). Participants who were married had lower rates of study discontinuation than their unmarried counterparts (27.0% vs. 39.8%, P = 0.001). Only 1 clinical measure was a statistically significant predictor of study discontinuation in the univariate analysis: participants with a HAM-D score of Z6 to 12 were more likely to discontinue than participants scoring <6 (HR = 1.6, P = 0.004). Participants in the donepezil arm were more likely to discontinue than participants in the placebo arm (HR = 2.2, P<0.001).
Per our prespecified model building algorithm, covariates selected for the final multivariate model based on a univariate log-rank test P-value <0.1 were treatment arm, site classification, marital status/informant relationship, education, gender, race/ethnicity, and HAM-D score. Age was not significantly related to study discontinuation at the P<0.1 level, but was forced into the model. Of potential pairwise interactions, only the gender by marital status term was statistically significant (likelihood ratio test P-value <0.0001); this interaction was added to the model using married men as the referent gender by marital status category. The 2 measures with univariate P-values between 0.1 and 0.15, the Beck Informant Depression Scale and the primary language indicator, were added separately to the model and tested for significance. Neither significantly improved the model (likelihood ratio test P-values >0.3), nor did their inclusion modify coefficients of covariates already in the model by more than 15%, and therefore these terms were not included in the final model. Proportional hazards assumptions were not rejected for any terms in the model (P>0.3) . The final multivariate model is presented in Table 2 . Hazard ratios and p-values in the full multivariate model are largely consist with those observe in the univariate analyses, although in the final model we observe that the effect of marital status on discontinuation is present only within men (HR = 2.24, P = 0.001 for unmarried vs. married men). The gender effect remains, but individual terms in the final model comparing married and unmarried women to the referent married men category are not statistically significant because of the reduced per comparison sample size. If these 2 female categories are pooled, the gender effect is statistically significant (HR = 1.34, P = 0.044 for women vs. married men).
When we reran the model censoring participants who died rather than counting them as study discontinuation events, the coefficients and P-values for all of the statistically significant predictors in Table 2 were not appreciably changed except for the HAM-D term, which was attenuated and no longer a significant predictor of study discontinuation (HR = 1.21, P = 0.27). When we reran the model further censoring both deaths and other serious adverse events, the coefficients for all of the significant predictors were not appreciably changed, although in this model the P-value for the education less than high school term became only marginally statistically significant (P-value changing from 0.02 to 0.07 after censoring of deaths and other serious adverse events).
The final disposition of study participants is summarized by type of clinical recruitment site in Table 3 . Participants recruited by commercial sites were less likely to convert to dementia, and more likely to die or discontinue compared with noncommercial sites. Reasons for voluntary study discontinuation by type of clinical recruitment site are summarized in Table 4 . ''Caregiver unwilling or unable to participate'' was the most commonly cited reason, scored by 35 of 160 caregivers (22%). There were no significant differences in the frequency of reasons by site type, although there was a trend toward participants recruited by commercial sites discontinuing because of concern that the treatment medication was not effective (P = 0.07) and a trend toward participants recruited by noncommercial sites discontinuing because of travel requirements (P = 0.06).
DISCUSSION
We found that participants in the donepezil arm had a 57% higher risk of study discontinuation compared with participants in the placebo arm after controlling for covariates ( Table 2 , HR = 1.57, P = 0.006). This association was described in the primary report of trial findings and is attributable to the known side-effect profile of cholinesterase inhibitor treatment. 9 We also found that participants with more depression symptoms reported on the HAM-D were more likely to discontinue the trial. Although we did not perform a formal competing risk analysis, when we refit the final model with censoring of those participants who discontinued owing to death, the HAM-D association with study termination was attenuated; this suggests that the association was mainly owing to depressive symptoms predicting death during the trial. In fact, participants with a HAM-D greater than or equal to 6 were more likely to die during the trial (5.6% died vs. 1.6% among participants with a HAM-D less than 6, Fisher exact test P-value = 0.016).
We also found that participants with less educational attainment and nonwhite participants had a higher rate of study discontinuation. Although minority race or ethnicity is a commonly perceived barrier to recruitment and retention, 6, 7 there are little published data on clinical trial retention rates as a function of race or ethnicity, and we know of no published data on this issue within the elderly. We found that commercial recruitment sites had twice the study discontinuation rate of noncommercial sites. All sites attended the same protocol training meetings and followed the same protocol. However, the commercial sites differ from the noncommercial sites in a number of ways. There are some indications the commercial sites recruited from a different pool of study participants. Although there was no difference between commercial and noncommercial sites in terms of the distribution of age, gender, and ethnicity, the participants recruited by commercial sites had slightly less education (mean 14.1 y vs. 14.8 y, Wilcoxon sign rank test P-value = 0.003). Lower education did predict a higher dropout rate in our sample (Table 1) . However, in the multivariate analysis with both education and site in the model the HR for commercial sites was unchanged and remained highly statistically significant ( Table 2) , indicating that the site effect was not mediated by education in any appreciable way. We also observed that, among participants who withdrew consent, caregivers from commercial sites were more likely to endorse as a reason for study discontinuation ''Concern about effectiveness of medications'' (26.0% vs. 14.5% for noncommercial sites). It is possible that recruitment methods at commercial sites increased the proportion of participants seeking active treatment through enrollment in clinical trials as opposed to participants participating for more altruistic motivations. Participants who seek active treatment through enrollment in clinical trials may be more likely to discontinue early if they perceive they are randomized to an arm with inactive or ineffective treatment (as reviewed in Vozdolska et al 23 ) . Participant from commercial sites were also more likely to die during the trial or to be discontinued because of other serious adverse events (Table 4 ). This does not entirely explain the higher loss rate in commercial sites, however. When the multivariate survival analysis was repeated with censoring of the deaths and adverse eventrelated discontinuations, the HR for commercial sites remained statistically significant (P = 0.0002) and was attenuated only modestly, from HR = 2.21 to HR = 2.09.
Beyond study participants characteristics, we also suspect that staff members at ADCs and universityaffiliated sites are more familiar with the scientific research process and more sensitive to the importance of complete data for the validity of a trial. Staff members at ADCs and university-affiliated sites often have developed skills and standards for maintaining study participant continuity in the course of their own research. These skills and standards may transfer to their performance of recruitment and retention for multicenter clinical trials. Furthermore, academic sites are more likely to recruit participants from their own clinic populations, whereas commercial sites tend to rely more heavily on advertising; longstanding relationships among staff and participants at academic sites may improve retention at these sites.
Early study discontinuation at commercial sites did reduce the statistical power of the ADCS MCI trial. Average person-years of observation for participants recruited by commercial sites was 1.75 person-years per participant recruited, compared with 2.01 person-years per participants recruited by ADC sites and 1.95 person-years per participants recruited by non-ADC university-affiliated sites. Compounding the high study discontinuation rate was a low incident dementia rate among participants recruited by commercial sites (Table 3 ). There were only 10.4 incident dementia cases per 100 person-years of observation at the commercial sites compared to 16.6 and 14.4 incident dementia cases per 100 person-years of observation at the ADC and university-affiliated sites. We speculate that this can be attributed to a lack of specificity of diagnosis for amnestic MCI by commercial sites when screening participants for inclusion in the ADCS MCI trial (the inclusion criteria specified that nonamnestic subtypes of MCI should not be enrolled). Clinicians at commercial sites may have been less sensitive than their ADC and university-affiliated research counterparts to those inclusion criteria intended to narrow recruitment to the amnestic subtype of MCI that is most consistent with prodromal AD.
Cumulatively, high study discontinuation rates and low incident dementia rates such as experienced by commercial sites in the ADCS MCI trial can substantially compromise statistical power. One practical measure of the effect of incidence rates and discontinuation rates on power is in the calculation of sample size requirements when planning future trials. The statistical power of a survival analysis is determined by the expected number of incident events observed. 24 During this 3-year trial, the commercial sites observed 0.1818 dementia events per study participant recruited, whereas the ADC sites observed 0.3333 dementia events per study participant recruited. On the basis of the number of events observed per participant recruited, a clinical trial using commercial sites with the discontinuation rates and incident dementia rates experienced in the ADCS MCI trial would require 1.8 times as many participants as a comparably powered clinical trial using ADC clinical sites.
CONCLUSIONS
Study participant dropout has been problematic for many MCI trials conducted to date (reviewed in Jelic et al 3 ) .
Missing data owing to study participant dropout compromises the power and validity of statistical analyses of trial results. We identified several demographic parameters that predict a higher dropout rate, including sex, marital status, education, and race/ethnicity. Retention efforts targeting the identified groups may improve the representativeness and power of future trials. We also found that commercial recruitment sites have a higher dropout rate and lower incident dementia rate than ADCs and university-affiliated sites. Overall, the ADCS MCI trial had a relatively low dropout rate compared with most MCI trials conducted to date, 3 presumably because the ADCS MCI trial was less reliant on commercial sites for recruitment. We conclude that utilization of academic sites could substantively decrease dropout and improve the statistical power and validity of future clinical trials of cognitively impaired elderly.
